Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autologous bone marrow transplantation in solid tumors.

G Spitzer1

  • 1St. Louis University Medical School, Missouri.

Current Opinion in Oncology
|April 1, 1991
PubMed
Summary

High-dose therapy with autologous marrow support improves long-term survival for various cancers, including breast cancer and neuroblastoma. Advances in supportive care show promise for treating resistant tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microcirculation in hypertensive patients.

Biorheology·2014
Same author

Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas.

Cancer journal (Sudbury, Mass.)·2009
Same author

Enhancing drug discovery through in silico screening: strategies to increase true positives retrieval rates.

Current medicinal chemistry·2008
Same author

Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer.

Clinical transplantation·2000
Same author

Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer.

JAMA·1999
Same author

Effects of allogeneic peripheral stem cell transplantation in a patient with job syndrome of hyperimmunoglobulinemia E and recurrent infections.

The American journal of medicine·1998

Area of Science:

  • Oncology
  • Hematology
  • Cancer Therapeutics

Background:

  • High-dose therapy (HDT) with autologous marrow support (AMS) has been investigated for various cancers.
  • Conventional therapy outcomes serve as a benchmark for evaluating HDT efficacy.
  • Marrow contamination and supportive care advancements are critical considerations in HDT.

Purpose of the Study:

  • To review recent studies on HDT with AMS in specific cancers.
  • To compare HDT outcomes with conventional therapy.
  • To explore potential improvements in HDT for resistant tumors.

Main Methods:

  • Review of recent clinical studies on HDT with AMS.
  • Analysis of disease-free survival rates in treated patient subgroups.
  • Comparison of outcomes between HDT and conventional therapy groups.

Main Results:

  • HDT with AMS demonstrated an increased proportion of long-term disease-free survivors in metastatic breast cancer, early-stage breast cancer, stage IV neuroblastoma, recurrent or bulky disease, and testicular cancer.
  • Conventional therapy showed comparatively lower long-term survival rates.
  • Emerging supportive care strategies, including recombinant growth factors and mobilized peripheral blood stem cells, alongside non-cross-resistant regimens, offer potential for further improvement.

Conclusions:

  • HDT with AMS is a valuable treatment modality, enhancing long-term survival in selected cancers.
  • Continued research into supportive care and novel therapeutic regimens is crucial for optimizing HDT outcomes and expanding its application to more challenging malignancies.
  • Addressing marrow contamination remains an important area of investigation.

Related Experiment Videos